Poor GMP/GDP Practice found in US Warehouse

Recommendation
9 September 2025
Basel, Switzerland
Specifics in the Distribution of Medicinal Products
Any contract giver is ultimately responsible for the product in the marketplace even where certain activities are contracted out. They are therefore responsible for defining appropriate controls in a clear written contract and monitor to ensure that the contract acceptor performs the outsourced activity as required. Audits should be undertaken at a frequency determined by the contract giver's risk assessment. If periodic audits of the contract acceptor are not frequent enough there is a risk that GMP and GDP standards slip without the contract giver being aware until a significant issue occurs.
What can go wrong for example in a warehouse was now published in a news release by the U.S. Food and Drug Administration FDA. In a warehouse in Arkansas, USA, which also stores and distributes over-the-counter (OTC) drugs obtained through brokers, observations were made beyond belief. The investigators found "alarming" insanitary conditions including "multiple live and dead rodents, rodent nesting, live raccoons, live cats, a dead possum, animal feces, and urine-stained products in and around the company's seven warehouses".
As a result, FDA issued two Administrative Detention Orders calling for the detention of all human and animal food products and drugs.
Source: FDA News Release "FDA seizes food and medical products held under insanitary conditions at an Arkansas grocery warehouse".
Related GMP News
14.05.2025Stimuli Article Proposes Revision of USP Definition of Controlled Room Temperature (CRT)
13.05.2025Survey on GDP Implementation
13.05.2025New Version of the HPRA GDP Guide Published
13.05.2025GDP in the US: Updates on Implementation of DSCSA
13.05.2025GDP Non-Compliance Report: No Responsible Person, proper Storage and Distribution not ensured
13.05.2025Questions and Answers from the ECA Webinar "GDP Update 2025" - Part 2